Impact of Halobetasol Propionate and Tazarotene Lotion 0.01%/0.045% in the Management of Plaque Psoriasis in Adults

Halobetasol propionate and tazarotene lotion 0.01%/0.045% (HP/TAZ) is a topical medication approved for the treatment of plaque psoriasis in adults. As a treatment modality, HP/TAZ has a combinatory therapeutic effect because it contains both a corticosteroid (HP) and a retinoid (TAZ) component. Her...

Descripción completa

Detalles Bibliográficos
Autores principales: Reddy, Vidhatha, Myers, Bridget, Yang, Eric J, Bhutani, Tina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7295208/
https://www.ncbi.nlm.nih.gov/pubmed/32606876
http://dx.doi.org/10.2147/CCID.S252426
_version_ 1783546608549363712
author Reddy, Vidhatha
Myers, Bridget
Yang, Eric J
Bhutani, Tina
author_facet Reddy, Vidhatha
Myers, Bridget
Yang, Eric J
Bhutani, Tina
author_sort Reddy, Vidhatha
collection PubMed
description Halobetasol propionate and tazarotene lotion 0.01%/0.045% (HP/TAZ) is a topical medication approved for the treatment of plaque psoriasis in adults. As a treatment modality, HP/TAZ has a combinatory therapeutic effect because it contains both a corticosteroid (HP) and a retinoid (TAZ) component. Here, we review the important clinical efficacy and safety data derived from pivotal clinical trials for HP/TAZ in the treatment of plaque psoriasis. We also discuss the mechanism of action, dosage guidelines, pharmacokinetics/pharmacodynamics, and clinical considerations for HP/TAZ, including why HP/TAZ should be avoided in pregnant patients.
format Online
Article
Text
id pubmed-7295208
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-72952082020-06-29 Impact of Halobetasol Propionate and Tazarotene Lotion 0.01%/0.045% in the Management of Plaque Psoriasis in Adults Reddy, Vidhatha Myers, Bridget Yang, Eric J Bhutani, Tina Clin Cosmet Investig Dermatol Review Halobetasol propionate and tazarotene lotion 0.01%/0.045% (HP/TAZ) is a topical medication approved for the treatment of plaque psoriasis in adults. As a treatment modality, HP/TAZ has a combinatory therapeutic effect because it contains both a corticosteroid (HP) and a retinoid (TAZ) component. Here, we review the important clinical efficacy and safety data derived from pivotal clinical trials for HP/TAZ in the treatment of plaque psoriasis. We also discuss the mechanism of action, dosage guidelines, pharmacokinetics/pharmacodynamics, and clinical considerations for HP/TAZ, including why HP/TAZ should be avoided in pregnant patients. Dove 2020-06-11 /pmc/articles/PMC7295208/ /pubmed/32606876 http://dx.doi.org/10.2147/CCID.S252426 Text en © 2020 Reddy et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Review
Reddy, Vidhatha
Myers, Bridget
Yang, Eric J
Bhutani, Tina
Impact of Halobetasol Propionate and Tazarotene Lotion 0.01%/0.045% in the Management of Plaque Psoriasis in Adults
title Impact of Halobetasol Propionate and Tazarotene Lotion 0.01%/0.045% in the Management of Plaque Psoriasis in Adults
title_full Impact of Halobetasol Propionate and Tazarotene Lotion 0.01%/0.045% in the Management of Plaque Psoriasis in Adults
title_fullStr Impact of Halobetasol Propionate and Tazarotene Lotion 0.01%/0.045% in the Management of Plaque Psoriasis in Adults
title_full_unstemmed Impact of Halobetasol Propionate and Tazarotene Lotion 0.01%/0.045% in the Management of Plaque Psoriasis in Adults
title_short Impact of Halobetasol Propionate and Tazarotene Lotion 0.01%/0.045% in the Management of Plaque Psoriasis in Adults
title_sort impact of halobetasol propionate and tazarotene lotion 0.01%/0.045% in the management of plaque psoriasis in adults
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7295208/
https://www.ncbi.nlm.nih.gov/pubmed/32606876
http://dx.doi.org/10.2147/CCID.S252426
work_keys_str_mv AT reddyvidhatha impactofhalobetasolpropionateandtazarotenelotion0010045inthemanagementofplaquepsoriasisinadults
AT myersbridget impactofhalobetasolpropionateandtazarotenelotion0010045inthemanagementofplaquepsoriasisinadults
AT yangericj impactofhalobetasolpropionateandtazarotenelotion0010045inthemanagementofplaquepsoriasisinadults
AT bhutanitina impactofhalobetasolpropionateandtazarotenelotion0010045inthemanagementofplaquepsoriasisinadults

Ejemplares similares